Xilio Therapeutics
Mar 03, 2020
Gilead to buy Forty Seven; Akrevia Therapeutics unveils new identity; FDA approved pyrimethamine
Gilead Sciences has announced to purchase an Immuno-oncology company Forty Seven for USD 95.50 per share, totalling up to a deal value of USD 4.9 billion. By acquiring Forty Seven – named after its lead molecule - CD47 tumor cell protein - Gilead will acquire its lead candidate, Magrolimab, adding value to its ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
